Tibisan Drug Interactions

Observed interactions resulting in a concomitant use not recommended.
Drugs that may decrease Imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity could increase metabolism and decrease Imatinib plasma concentration. Co-medications which induce CYP3A4 (e.g. Dexamethasone, Phenytoin, Carbamazepine, Rifampicin, Phenobarbital or Hypericum Perforatum also known as St. John’s Wort) may significantly reduce exposure to Imatinib. In patients where Rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.
Other interactions that may effect exposure to Imatinib or other drugs.
Drugs that may increased Imatinib plasma concentrations: Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g Ketoconazole, Itraconazole, Erythromycin, Clarythromycin) could decrease metabolism and increase Imatinib concentrations. Caution should be taken when administering Imatinib with inhibitors of the CYP3A4 family.
Drug that may have their plasma concentration altered by Imatinib: Imatinib increases the mean Cmax and AUC of Simvastatin (CYP3A4 substrate), indicating an inhibition of the CYP3A4 by Imatinib. Therefore, caution is recommended when administering Imatinib with CYP3A4 substrates with a narrow therapeutic window (e.g. Cyclosporin or Pimozide). Imatinib may increase plasma concentration of other CYP3A4 metabolized drugs (e.g.Triazolo-Benzodiazepines, Dihydropyridine Calcium Channel Blockers, certain HMG-CoA Reductase Inhibitors, i.e. Statins, etc.).
Imatinib also inhibits CYP2C9 and CYP2C19 activity.